The Chemours Company Logo

The Chemours Company

CC

(1.0)
Stock Price

19,23 USD

-3.93% ROA

-31.61% ROE

-14.62x PER

Market Cap.

4.496.187.020,00 USD

552.85% DER

3.3% Yield

-5.13% NPM

The Chemours Company Stock Analysis

The Chemours Company Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

The Chemours Company Fundamental Stock Analysis
# Analysis Rating
1 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

2 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

3 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (31) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

4 ROE

Negative ROE (-31.61%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-3.93%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 PBV

The stock's elevated P/BV ratio (5.37x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 DER

The company has a high debt to equity ratio (553%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

8 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

10 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

The Chemours Company Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

The Chemours Company Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

The Chemours Company Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

The Chemours Company Revenue
Year Revenue Growth
2011 7.972.000.000
2012 7.365.000.000 -8.24%
2013 6.859.000.000 -7.38%
2014 6.432.000.000 -6.64%
2015 5.717.000.000 -12.51%
2016 5.400.000.000 -5.87%
2017 6.183.000.000 12.66%
2018 6.638.000.000 6.85%
2019 5.526.000.000 -20.12%
2020 4.969.000.000 -11.21%
2021 6.345.000.000 21.69%
2022 6.794.000.000 6.61%
2023 5.948.000.000 -14.22%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

The Chemours Company Research and Development Expenses
Year Research and Development Expenses Growth
2011 135.000.000
2012 145.000.000 6.9%
2013 164.000.000 11.59%
2014 143.000.000 -14.69%
2015 97.000.000 -47.42%
2016 80.000.000 -21.25%
2017 80.000.000 0%
2018 82.000.000 2.44%
2019 80.000.000 -2.5%
2020 93.000.000 13.98%
2021 107.000.000 13.08%
2022 118.000.000 9.32%
2023 112.000.000 -5.36%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

The Chemours Company General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 731.000.000
2012 747.000.000 2.14%
2013 768.000.000 2.73%
2014 685.000.000 -12.12%
2015 632.000.000 -8.39%
2016 934.000.000 32.33%
2017 602.000.000 -55.15%
2018 657.000.000 8.37%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

The Chemours Company EBITDA
Year EBITDA Growth
2011 1.926.000.000
2012 1.766.000.000 -9.06%
2013 826.000.000 -113.8%
2014 836.000.000 1.2%
2015 559.000.000 -49.55%
2016 656.000.000 14.79%
2017 1.457.000.000 54.98%
2018 1.721.000.000 15.34%
2019 482.000.000 -257.05%
2020 829.000.000 41.86%
2021 1.205.000.000 31.2%
2022 1.204.000.000 -0.08%
2023 352.000.000 -242.05%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

The Chemours Company Gross Profit
Year Gross Profit Growth
2011 2.597.000.000
2012 2.351.000.000 -10.46%
2013 1.464.000.000 -60.59%
2014 1.360.000.000 -7.65%
2015 955.000.000 -42.41%
2016 1.110.000.000 13.96%
2017 1.754.000.000 36.72%
2018 1.971.000.000 11.01%
2019 1.063.000.000 -85.42%
2020 1.067.000.000 0.37%
2021 1.381.000.000 22.74%
2022 1.616.000.000 14.54%
2023 1.124.000.000 -43.77%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

The Chemours Company Net Profit
Year Net Profit Growth
2011 1.431.000.000
2012 1.057.000.000 -35.38%
2013 423.000.000 -149.88%
2014 400.000.000 -5.75%
2015 -90.000.000 544.44%
2016 7.000.000 1385.71%
2017 746.000.000 99.06%
2018 995.000.000 25.03%
2019 -52.000.000 2013.46%
2020 219.000.000 123.74%
2021 608.000.000 63.98%
2022 578.000.000 -5.19%
2023 80.000.000 -622.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

The Chemours Company Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 8
2012 6 -40%
2013 2 -150%
2014 2 0%
2015 -1 0%
2016 0 0%
2017 4 100%
2018 6 20%
2019 0 0%
2020 1 100%
2021 4 66.67%
2022 4 0%
2023 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

The Chemours Company Free Cashflow
Year Free Cashflow Growth
2011 1.141.000.000
2012 958.000.000 -19.1%
2013 360.000.000 -166.11%
2014 -99.000.000 463.64%
2015 -337.000.000 70.62%
2016 256.000.000 231.64%
2017 228.000.000 -12.28%
2018 642.000.000 64.49%
2019 169.000.000 -279.88%
2020 540.000.000 68.7%
2021 543.000.000 0.55%
2022 447.000.000 -21.48%
2023 44.000.000 -915.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

The Chemours Company Operating Cashflow
Year Operating Cashflow Growth
2011 1.496.000.000
2012 1.390.000.000 -7.63%
2013 798.000.000 -74.19%
2014 505.000.000 -58.02%
2015 182.000.000 -177.47%
2016 594.000.000 69.36%
2017 639.000.000 7.04%
2018 1.140.000.000 43.95%
2019 650.000.000 -75.38%
2020 807.000.000 19.45%
2021 820.000.000 1.59%
2022 754.000.000 -8.75%
2023 130.000.000 -480%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

The Chemours Company Capital Expenditure
Year Capital Expenditure Growth
2011 355.000.000
2012 432.000.000 17.82%
2013 438.000.000 1.37%
2014 604.000.000 27.48%
2015 519.000.000 -16.38%
2016 338.000.000 -53.55%
2017 411.000.000 17.76%
2018 498.000.000 17.47%
2019 481.000.000 -3.53%
2020 267.000.000 -80.15%
2021 277.000.000 3.61%
2022 307.000.000 9.77%
2023 86.000.000 -256.98%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

The Chemours Company Equity
Year Equity Growth
2012 3.227.000.000
2013 3.276.000.000 1.5%
2014 3.669.000.000 10.71%
2015 126.000.000 -2811.9%
2016 100.000.000 -26%
2017 860.000.000 88.37%
2018 1.020.000.000 15.69%
2019 695.000.000 -46.76%
2020 815.000.000 14.72%
2021 1.082.000.000 24.68%
2022 1.107.000.000 2.26%
2023 757.000.000 -46.24%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

The Chemours Company Assets
Year Assets Growth
2012 5.317.000.000
2013 5.621.000.000 5.41%
2014 5.978.000.000 5.97%
2015 6.298.000.000 5.08%
2016 6.060.000.000 -3.93%
2017 7.293.000.000 16.91%
2018 7.362.000.000 0.94%
2019 7.258.000.000 -1.43%
2020 7.082.000.000 -2.49%
2021 7.550.000.000 6.2%
2022 7.640.000.000 1.18%
2023 7.948.000.000 3.88%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

The Chemours Company Liabilities
Year Liabilities Growth
2012 2.088.000.000
2013 2.342.000.000 10.85%
2014 2.305.000.000 -1.61%
2015 6.168.000.000 62.63%
2016 5.956.000.000 -3.56%
2017 6.428.000.000 7.34%
2018 6.342.000.000 -1.36%
2019 6.563.000.000 3.37%
2020 6.267.000.000 -4.72%
2021 6.468.000.000 3.11%
2022 6.533.000.000 0.99%
2023 7.191.000.000 9.15%

The Chemours Company Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
40.4
Net Income per Share
-2.07
Price to Earning Ratio
-14.62x
Price To Sales Ratio
0.75x
POCF Ratio
19.4
PFCF Ratio
-64.23
Price to Book Ratio
5.96
EV to Sales
1.3
EV Over EBITDA
43.43
EV to Operating CashFlow
33.7
EV to FreeCashFlow
-111.69
Earnings Yield
-0.07
FreeCashFlow Yield
-0.02
Market Cap
4,50 Bil.
Enterprise Value
7,82 Bil.
Graham Number
15.39
Graham NetNet
-33.96

Income Statement Metrics

Net Income per Share
-2.07
Income Quality
-0.75
ROE
-0.32
Return On Assets
-0.04
Return On Capital Employed
-0.01
Net Income per EBT
1.01
EBT Per Ebit
4.94
Ebit per Revenue
-0.01
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.21
Operating Profit Margin
-0.01
Pretax Profit Margin
-0.05
Net Profit Margin
-0.05

Dividends

Dividend Yield
0.03
Dividend Yield %
3.3
Payout Ratio
-0.48
Dividend Per Share
1

Operating Metrics

Operating Cashflow per Share
1.56
Free CashFlow per Share
-0.47
Capex to Operating CashFlow
-1.3
Capex to Revenue
-0.05
Capex to Depreciation
-0.98
Return on Invested Capital
-0.01
Return on Tangible Assets
-0.04
Days Sales Outstanding
51.43
Days Payables Outstanding
69.34
Days of Inventory on Hand
101.12
Receivables Turnover
7.1
Payables Turnover
5.26
Inventory Turnover
3.61
Capex per Share
-2.03

Balance Sheet

Cash per Share
5,73
Book Value per Share
5,08
Tangible Book Value per Share
4.37
Shareholders Equity per Share
5.08
Interest Debt per Share
28.59
Debt to Equity
5.53
Debt to Assets
0.53
Net Debt to EBITDA
18.46
Current Ratio
1.68
Tangible Asset Value
0,65 Bil.
Net Current Asset Value
-3,51 Bil.
Invested Capital
5.53
Working Capital
1,49 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,87 Bil.
Average Payables
0,96 Bil.
Average Inventory
1380000000
Debt to Market Cap
0.93

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

The Chemours Company Dividends
Year Dividends Growth
2015 1
2016 0 0%
2017 0 0%
2018 1 0%
2019 1 100%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%

The Chemours Company Profile

About The Chemours Company

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical, and others applications. The Chemical Solutions segment comprises a portfolio of industrial chemicals used as raw materials and catalysts for gold production, clean and disinfect, oil and gas, water treatment, electronics, and automotive applications. The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.

CEO
Ms. Denise M. Dignam
Employee
6.600
Address
1007 Market Street
Wilmington, 19899

The Chemours Company Executives & BODs

The Chemours Company Executives & BODs
# Name Age
1 Mr. Matthew S. Abbott
Interim Chief Financial Officer and Principal Financial & Accounting Officer
70
2 Ms. Kristine M. Wellman
Senior Vice President, General Counsel & Company Secretary
70
3 Mr. Joseph Martinko
President of Thermal & Specialized Solutions
70
4 Mr. Aditya Beri
Interim President of Titanium Technologies & Chemical Solutions Business
70
5 Ms. Denise M. Dignam
Interim Chief Executive Officer & President of Titanium Technologies
70
6 Mr. Ron Charles
Senior Vice President of People
70
7 Mr. Gerardo Familiar Calderon
President of Advanced Performance Materials
70
8 Ms. Alvenia Scarborough
Senior Vice President of Corporate Communications & Chief Brand Officer
70
9 Ms. Amber Wellman Ph.D.
Chief Sustainability Officer
70
10 Mr. Brandon Ontjes
Vice President of FP&A and Investor Relations
70

The Chemours Company Competitors